AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24662777 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ezetimibe and simvastatin (n = 24)
Number of subjects: 72
Study 22510027 — intervention group
Group type: EXPERIMENTAL
Intervention: GerdQ-based algorithm (NSP)
Number of subjects: 280
Study 22510027 — intervention group
Group type: COMPARATOR
Intervention: Endoscopy-based approach (OCP)
Number of subjects: 280
Study 20803425 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/day fish oil capsule (with 180 mg EPA and 120 mg DHA, totaling 300 mg n-3 fatty acids)
Number of subjects: 124
Study 20803425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 18070852 — intervention group
Group type: EXPERIMENTAL
Intervention: Active 10 Hz suprathreshold rTMS to the left dorsolateral prefrontal cortex
Number of subjects: 10
Study 18070852 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 10
Study 15992878 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable, camera-less laparoscopic trainer (group 1)
Number of subjects: 22
Study 15992878 — intervention group
Group type: COMPARATOR
Intervention: Standard video laparoscopic trainer (group 2)
Number of subjects: 22
Study 12610804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cyclical etidronate therapy (ICET)
Number of subjects: 63
Study 12610804 — intervention group
Group type: COMPARATOR
Intervention: Non-ICET group
Number of subjects: 63
Study 10333100 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with three different treatment parameters
Number of subjects: 9
Study 10333100 — intervention group
Group type: COMPARATOR
Intervention: Fluorescein angiography (FA) examinations
Number of subjects: 9
Study 7734269 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 126
Study 7734269 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 126
Study 7734269 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% ropivacaine
Number of subjects: 126
Study 7734269 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 126
Study 7734269 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of ropivacaine
Number of subjects: 126
Study 2340607 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanic nerve stimulation (50 Hz, 5 sec)
Number of subjects: 44
Study 2340607 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical tactile assessment of the response to tetanic stimulation
Number of subjects: 44
Study 373071 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 400 mg twice daily
Number of subjects: 19
Study 373071 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive tablets)
Number of subjects: 19
Study 30803886 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oxygen (n=214)
Number of subjects: 359
Study 30803886 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent oxygen (n=145)
Number of subjects: 359
Study 29798953 — intervention group
Group type: EXPERIMENTAL
Intervention: BevaciRel™ bevacizumab (study bevacizumab)
Number of subjects: 119
Study 29798953 — intervention group
Group type: COMPARATOR
Intervention: Reference bevacizumab
Number of subjects: 119
Study 26051575 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger essential oil inhalation
Number of subjects: 60
Study 23924144 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NEMEX-TJR) for 12 weeks (mean, SD 5.6)
Number of subjects: 87
Study 23924144 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NEMEX-TJR)
Number of subjects: 87
Study 23924144 — intervention group
Group type: COMPARATOR
Intervention: Reference group (age-matched population-based)
Number of subjects: 87
Study 21310101 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate and benzydamine hydrochloride mouth spray (n = 72)
Number of subjects: 147
Study 21310101 — intervention group
Group type: COMPARATOR
Intervention: Penicillin plus placebo (n = 75)
Number of subjects: 147
Study 19725009 — intervention group
Group type: EXPERIMENTAL
Intervention: Natriuretic peptides (NP)
Number of subjects: 0
Study 16955106 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow treatment (cyclers with high dialysate flow, no manual daytime exchange)
Number of subjects: 18
Study 16955106 — intervention group
Group type: COMPARATOR
Intervention: Manual exchange treatment (conventional APD with low nightly dialysate flow and one manual daytime exchange)
Number of subjects: 18
Study 15727144 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg/week for 8 weeks (R1)
Number of subjects: 1693
Study 15727144 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1500 mg once upon enrolment (R2)
Number of subjects: 1693
Study 15727144 — intervention group
Group type: COMPARATOR
Intervention: No drugs (R3)
Number of subjects: 1693
Study 11516807 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine 1 mg bd
Number of subjects: 251
Study 11516807 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine 2 mg bd
Number of subjects: 251
Study 11516807 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 251
Study 9220215 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac (50 or 100 mg)
Number of subjects: 238
Study 9220215 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg/oxycodone 10 mg
Number of subjects: 238
Study 9220215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 238
Study 9220215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 9220215 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac (multiple doses)
Number of subjects: 238
Study 9220215 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen/oxycodone (multiple doses)
Number of subjects: 238
Study 9220215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (multiple doses)
Number of subjects: 238
Study 8314271 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual nifedipine 10 mg
Number of subjects: 52
Study 8314271 — intervention group
Group type: COMPARATOR
Intervention: sublingual captopril 25 mg
Number of subjects: 52
Study 3321891 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 30
Study 3321891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31089955 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Number of subjects: 4
Study 31089955 — intervention group
Group type: COMPARATOR
Intervention: Control treatment as usual
Number of subjects: 4
Study 31089955 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy volunteers neurofeedback training
Number of subjects: 4
Study 30425114 — intervention group
Group type: EXPERIMENTAL
Intervention: IntelliVue (ECG plus Masimo pulse oximeter)
Number of subjects: 100
Study 30425114 — intervention group
Group type: COMPARATOR
Intervention: Nellcor (pulse oximeter alone)
Number of subjects: 100
Study 27412395 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy boost (15–20 Gy over 2 days with 192Ir needle)
Number of subjects: 52
Study 27412395 — intervention group
Group type: EXPERIMENTAL
Intervention: Electron beam therapy boost (20 Gy in 10 fractions over 2 weeks)
Number of subjects: 52
Study 26175290 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health intervention (3 sessions, booklet, mobile phone text-message reminders)
Number of subjects: 90
Study 26175290 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study 24260872 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural restrictions after repositioning maneuvers
Number of subjects: 68
Study 24260872 — intervention group
Group type: COMPARATOR
Intervention: No postural restrictions after treatment
Number of subjects: 68
Study 21978929 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol + normal saline (NS)
Number of subjects: 120
Study 21978929 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol + hypertonic saline (HS)
Number of subjects: 120
Study 21978929 — intervention group
Group type: EXPERIMENTAL
Intervention: hypertonic saline (HS)
Number of subjects: 120
Study 21978929 — intervention group
Group type: EXPERIMENTAL
Intervention: normal saline (NS)
Number of subjects: 120
Study 18645164 — intervention group
Group type: EXPERIMENTAL
Intervention: IGIV-C 10% at 0.2 g/kg
Number of subjects: 127
Study 18645164 — intervention group
Group type: EXPERIMENTAL
Intervention: IGIV-C 10% at 0.4 g/kg
Number of subjects: 127
Study 18645164 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.1% albumin)
Number of subjects: 127
Study 18645164 — intervention group
Group type: EXPERIMENTAL
Intervention: IGIV-C 10% at 0.2 g/kg and 0.4 g/kg
Number of subjects: 127
Study 17073201 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone treatment
Number of subjects: 28
Study 17073201 — intervention group
Group type: COMPARATOR
Intervention: Control (no ozone treatment)
Number of subjects: 28
Study 15583920 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA/PGA bioresorbable membrane combined with Bio-Oss implantation
Number of subjects: 28
Study 15583920 — intervention group
Group type: COMPARATOR
Intervention: Collagen bioresorbable membrane combined with Bio-Oss implantation
Number of subjects: 28
Study 11751737 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic pulse contour analysis
Number of subjects: 91
Study 11751737 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic pulse contour analysis (modified Windkessel model)
Number of subjects: 91
Study 11751737 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular (brachial) artery compliance by cuff plethysmography
Number of subjects: 91
Study 11751737 — intervention group
Group type: EXPERIMENTAL
Intervention: CTTI
Number of subjects: 91
Study 11751737 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance-related variables
Number of subjects: 91
Study 11751737 — intervention group
Group type: EXPERIMENTAL
Intervention: C(2)
Number of subjects: 91
Study 9024012 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-up (HU) positioning
Number of subjects: 80
Study 9024012 — intervention group
Group type: COMPARATOR
Intervention: Arms at side (AAS) positioning
Number of subjects: 80
Study 9024012 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HU and AAS)
Number of subjects: 80
Study 8512373 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative educational technique using pocket-sized problem-solving cards
Number of subjects: 0
Study 8512373 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8512373 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups (experimental and control)
Number of subjects: 0
Study 3646360 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium intake (250 mEq/day)
Number of subjects: 0
Study 3646360 — intervention group
Group type: COMPARATOR
Intervention: Low sodium intake (10 mEq/day)
Number of subjects: 0
Study 3646360 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute saline load during high sodium intake
Number of subjects: 0
Study 3646360 — intervention group
Group type: EXPERIMENTAL
Intervention: Water load during high sodium intake
Number of subjects: 0
Study 30513530 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency repetitive transcranial magnetic stimulation (rTMS) for 30 minutes, 5 days per week for 2 weeks
Number of subjects: 13
Study 30513530 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 13
Study 23696155 — intervention group
Group type: EXPERIMENTAL
Intervention: Payment card format (monthly and yearly variants)
Number of subjects: 0
Study 23696155 — intervention group
Group type: EXPERIMENTAL
Intervention: Binary response filter prior to payment card follow-up
Number of subjects: 0
Study 23696155 — intervention group
Group type: EXPERIMENTAL
Intervention: Payment card format with filter
Number of subjects: 0
Study 23696155 — intervention group
Group type: COMPARATOR
Intervention: Open-ended contingent valuation format
Number of subjects: 0
Study 22231607 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin medication use
Number of subjects: 153840
Study 22231607 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin medication use (multivariate-adjusted)
Number of subjects: 153840
Study 22231607 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal measures of statin use
Number of subjects: 153840
Study 19996415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow-derived progenitor cells (BMC)
Number of subjects: 204
Study 18235048 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine +/‐ perindopril
Number of subjects: 19257
Study 18235048 — intervention group
Group type: COMPARATOR
Intervention: Atenolol +/‐ thiazide
Number of subjects: 19257
Study 18235048 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline fasting plasma glucose (FPG) >5 mmol/l
Number of subjects: 19257
Study 18235048 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile of risk score
Number of subjects: 19257
Study 16192543 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulating catheter (Group S); bolus dose of 25 mL of 1.5% mepivacaine followed by a postoperative patient-controlled infusion of 0.2% ropivacaine (basal infusion: 3 mL/h; incremental dose: 5 mL; lockout time: 30 min).
Number of subjects: 100
Study 16192543 — intervention group
Group type: COMPARATOR
Intervention: Conventional nonstimulating catheter (Group C); bolus dose of 25 mL of 1.5% mepivacaine followed by a postoperative patient-controlled infusion of 0.2% ropivacaine (basal infusion: 3 mL/h; incremental dose: 5 mL; lockout time: 30 min).
Number of subjects: 100
Study 12569298 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (2500 mg/m2/day for 14 days every 21 days)
Number of subjects: 154
Study 11352130 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory evoked potentials (AEPs) obtained from two sequences of 288 stimuli of different intensities (60, 80, 90, and 110 dB SPL)
Number of subjects: 21
Study 11352130 — intervention group
Group type: EXPERIMENTAL
Intervention: A/R measures
Number of subjects: 21
Study 9391938 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based critiques presented at the time of ordering a KUB during Phase 1 (9-week period)
Number of subjects: 684
Study 9391938 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based critiques amended to include institutional data and stronger messages about the lack of utility during Phase 2 (19-week period)
Number of subjects: 684
Study 7806677 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive periodontal care with stringent plaque control (Group A)
Number of subjects: 23
Study 7806677 — intervention group
Group type: COMPARATOR
Intervention: Sporadic care (Group B)
Number of subjects: 23
Study 3075474 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination of CsA, azathioprine (AZA), and corticosteroids
Number of subjects: 202
Study 3075474 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic combination of CsA, corticosteroids, and antilymphocyte globulins (ALG)
Number of subjects: 202
Study 3075474 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA dose lower than or equal to 5 mg/kg per day
Number of subjects: 202
Study 3075474 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged ischemia time and grafts that did not function immediately
Number of subjects: 202
Study 3075474 — intervention group
Group type: EXPERIMENTAL
Intervention: More than 1 rejection crisis
Number of subjects: 202
Study 3075474 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA matching, peak panel reactivity, age of the recipient, occurrence of post‐transplant renal dysfunction, and 1‐month renal function
Number of subjects: 202
Study 30153954 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg)
Number of subjects: 31
Study 30153954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 27401305 — intervention group
Group type: EXPERIMENTAL
Intervention: FTS pathway
Number of subjects: 260
Study 27401305 — intervention group
Group type: COMPARATOR
Intervention: Conventional pathway
Number of subjects: 260
Study 24948653 — intervention group
Group type: COMPARATOR
Intervention: Daily pasture DM allowance of 3.5% of BW (LO)
Number of subjects: 203
Study 24948653 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily pasture DM allowance of 7.0% of BW (HI)
Number of subjects: 203
Study 23540073 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical preparations (novel formulations)
Number of subjects: 10
Study 23540073 — intervention group
Group type: COMPARATOR
Intervention: Standard (comparator) formulation
Number of subjects: 10
Study 23540073 — intervention group
Group type: COMPARATOR
Intervention: Untreated site (normal skin)
Number of subjects: 10
Study 23540073 — intervention group
Group type: COMPARATOR
Intervention: Untreated occluded site (chamber only)
Number of subjects: 10
Study 20450622 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant transarterial chemoembolization (TACE)
Number of subjects: 2591
Study 20450622 — intervention group
Group type: COMPARATOR
Intervention: Control group (resection alone)
Number of subjects: 2591
Study 18838525 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine-loading (100mg/Kg body weight) with vitamins C (2g) plus E (800IU)
Number of subjects: 28
Study 18838525 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (no vitamins)
Number of subjects: 28
Study 18838525 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins
Number of subjects: 28
Study 17243327 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralized cancellous bone allograft (Puros)
Number of subjects: 13
Study 17243327 — intervention group
Group type: COMPARATOR
Intervention: Anorganic bovine bone matrix (Bio-Oss)
Number of subjects: 13
Study 12792207 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (100% oxygen for 60 minutes at 2.0 ATA)
Number of subjects: 16
Study 12792207 — intervention group
Group type: COMPARATOR
Intervention: Normoxic air (21% oxygen at 1.2 ATA)
Number of subjects: 16
Study 11190455 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 18
Study 11190455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9000314 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body electromagnetic coil exposure at 34 or 100 microT
Number of subjects: 1
Study 9000314 — intervention group
Group type: COMPARATOR
Intervention: Sham exposures
Number of subjects: 1
Study 1535568 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg b.i.d. for 6 months
Number of subjects: 735
Study 1535568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 735
Study 1535568 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 735
Study 1535568 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 735
Study 30118368 — intervention group
Group type: EXPERIMENTAL
Intervention: m‐AIP (intrathecal injection of m‐AIP, a specific antagonist of CaMKII)
Number of subjects: 0
Study 30118368 — intervention group
Group type: EXPERIMENTAL
Intervention: m‐AIP (postoperative treatment)
Number of subjects: 0
Study 30118368 — intervention group
Group type: COMPARATOR
Intervention: Control (Sham and CCI groups)
Number of subjects: 0
Study 27470226 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally competent sexual health education interventions
Number of subjects: 99
Study 25727586 — intervention group
Group type: EXPERIMENTAL
Intervention: Plano lens with atropine
Number of subjects: 73
Study 25727586 — intervention group
Group type: COMPARATOR
Intervention: Atropine only
Number of subjects: 73
Study 23718905 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists' recommendations
Number of subjects: 2026
Study 23029977 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 13
Study 23029977 — intervention group
Group type: COMPARATOR
Intervention: Health coaching
Number of subjects: 13
Study 20708966 — intervention group
Group type: EXPERIMENTAL
Intervention: IRIS (irinotecan plus oral S-1)
Number of subjects: 426
Study 20708966 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI (folinic acid and irinotecan plus bolus and continuous infusion of fluorouracil)
Number of subjects: 426
Study 20708966 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 426
Study 20708966 — intervention group
Group type: EXPERIMENTAL
Intervention: IRIS
Number of subjects: 426
Study 17996772 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed reduction and plaster
Number of subjects: 87
Study 15789594 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual Information (MI) registration
Number of subjects: 12
Study 15789594 — intervention group
Group type: COMPARATOR
Intervention: Seed-match registration
Number of subjects: 12
Study 12470103 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hepatic inflow clamping (group T; n = 28)
Number of subjects: 58
Study 12470103 — intervention group
Group type: COMPARATOR
Intervention: Selective clamping of ipsilateral blood inflow (group H; n = 30)
Number of subjects: 58
Study 12470103 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (T and H)
Number of subjects: 58
Study 9491438 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate (HR) following personal stressful events
Number of subjects: 31
Study 9491438 — intervention group
Group type: EXPERIMENTAL
Intervention: Galvanic Skin Response (GSR) following personal stressful events
Number of subjects: 31
Study 9491438 — intervention group
Group type: COMPARATOR
Intervention: Heart Rate (HR) for neutral statements
Number of subjects: 31
Study 9491438 — intervention group
Group type: COMPARATOR
Intervention: Galvanic Skin Response (GSR) for neutral statements
Number of subjects: 31
Study 7877303 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized pump perfusion
Number of subjects: 15
Study 2194188 — intervention group
Group type: EXPERIMENTAL
Intervention: Picolax
Number of subjects: 0
Study 2194188 — intervention group
Group type: COMPARATOR
Intervention: Klyx enemas
Number of subjects: 0
Study 369006 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic injection group (sclerotherapy with ethanolamine oleate)
Number of subjects: 31
Study 369006 — intervention group
Group type: COMPARATOR
Intervention: Control group (conservative medical management)
Number of subjects: 31
Study 31942704 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrete-time hazard analysis applied to response times in visual search tasks
Number of subjects: 0